Elias D. Papadimas Net Worth

The estimated Net Worth of Elias D. Papadimas is at least $15.5 Tisíc dollars as of 27 August 2021. Mr Papadimas owns over 10,000 units of Exicure Inc stock worth over $15,500 and over the last 3 years he sold XCUR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Papadimas XCUR stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Exicure Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of XCUR stock worth $13,800 on 27 August 2021.

The largest trade he's ever made was buying 10,000 units of Exicure Inc stock on 27 August 2021 worth over $13,800. On average, Mr trades about 5,000 units every 0 days since 2021. As of 27 August 2021 he still owns at least 10,000 units of Exicure Inc stock.

You can see the complete history of Mr Papadimas stock trades at the bottom of the page.

Mr. Elias D. Papadimas biography

Elias D. Papadimas is the Chief Accounting Officer at Exicure Inc.

What's Mr Papadimas's mailing address?

Elias's mailing address filed with the SEC is C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO, IL, 60614.

Insiders trading at Exicure Inc

Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp a Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.

What does Exicure Inc do?

exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Complete history of Mr Papadimas stock trades at Exicure Inc

Exicure Inc executives and stock owners

Exicure Inc executives and other stock owners filed with the SEC include:

• David Giljohann,
  Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director
• Matthias Schroff,
  Chief Operating Officer
• Dr. Douglas E. Feltner,
  Chief Medical Officer
• Chad Mirkin,
  Director
• Bali Muralidhar,
  Independent Director
• Bosun Hau,
  Independent Director
• Jay Venkatesan,
  Independent Director
• Helen Kim,
  Independent Director
• Timothy Walbert,
  Independent Chairman of the Board
• David Walt,
  Independent Director
• Jeffrey Cleland,
  Independent Director
• Karen Sharma,
  Investor Relations
• Bart Anderson,
  Sr. Director of R&D
• Dr. Emil M. deGoma M.D.,
  VP of Clinical Devel.
• Weston Daniel,
  VP of Translational Research
• Sarah Longoria,
  VP of HR
• Christoph Jaeker,
  VP of Corp. Devel. & Strategy
• Elias D. Papadimas,
  Chief Accounting Officer
• Brian C. Bock,
  Chief Financial Officer
• Elizabeth A. Garofalo,
  Director
• Andy Sassine,
  Director
• Llc Aurasense,
  10% owner
• Douglas E. Feltner,
  Chief Medical Officer
• James R Sulat,
  Director
• Colby Shad Thaxton,
  Director
• David S Snyder,
  Chief Financial Officer
• Frontier, Llcgates William ...,
  
• Brian Bock,
  Chief Financial Officer
• Co., Ltd. Dgp,
  
• Elias D. Papadimas,
  Chief Financial Officer
• Sarah Longoria,
  Chief HR & Compliance Officer
• Usa, Inc. Cbi,
  
• Jiyoung Hwang,
  Director
• Josh Miller,
  Chief Accounting Officer